Authors

Latest:

Dr Borthakur on the SELECT MDS-1 Trial in Newly Diagnosed MDS

Gautam Borthakur, MD, discusses the ongoing phase 3 SELECT MDS-1 trial in patients with newly diagnosed myelodysplastic syndromes.

Akash Mukherjee, MD

Latest:

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Sandra Mazzoni, DO

Latest:

Dr Mazzoni on the Use of Quadruplet Regimens in Newly Diagnosed Myeloma

Sandra Mazzoni, DO, discusses the emerging role of quadruplet regimens in newly diagnosed multiple myeloma.

UW School of Medicine

Latest:

UW Carbone Cancer Center Receives SPORE Designation, Federal Grant to Support Prostate Cancer Research

University of Wisconsin Carbone Cancer Center will be designated as a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute for research initiatives to advance new prostate cancer treatments.

Sally Lau, MD

Latest:

Dr Lau on Tarlatamab as Maintenance Therapy in Extensive-Stage SCLC

Sally Lau, MD, discusses the addition of tarlatamab to a PD-L1 inhibitor as first-line maintenance therapy for extensive-stage small cell lung cancer.

Nasser Khaled Altorki, MD

Latest:

Dr. Altorki on the Results of Post-Hoc Analyses of the IMpower010 Trial in NSCLC

Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.

Milind Javle, MD, The University of Texas MD Anderson Cancer Center

Latest:

The Investigational Pipeline for Advanced BTC

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Pierre Gholam, MD

Latest:

Dr Gholam on Camrelizumab Plus Rivoceranib in Unresectable HCC

Pierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.

Arpit Rao, MD

Latest:

Dr. Rao on the Rationale of the CASPAR Trial in mCRPC

Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.

Julio Gutierrez, MD

Latest:

Safety Profiles of Available Therapies in Advanced HCC

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Afsaneh Barzi, MD, PhD

Latest:

Dr Barzi on the Real-World Use of Triplet Chemotherapies in mCRC

Afsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.

Hans C. Lee, MD

Latest:

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

Amandeep Salhotra, MD

Latest:

OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

Neil J. Shah, MBBS

Latest:

Dr Shah on Real-World Treatment and Outcomes in Metastatic RCC After IO/TKI Combos

Neil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.

Félix Guerrero-Ramos, MD, PhD, FEBU

Latest:

Dr. Ramos on the Role of BCG In Non-Muscle Invasive Bladder Cancer

Félix Guerrero-Ramos, MD, PhD, FEBU, discusses the role of Bacillus Calmette-Guerin in the treatment of patients with non-muscle invasive bladder cancer.

Lucy Gilbert, MD, MSc

Latest:

Dr. Gilbert on Evaluating Mirvetuximab Soravtansine in Platinum-Agnostic Ovarian Cancer

Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Khalid Matin, MD, FACP

Latest:

Community-Based Programs Have the Power to Remove Clinical Trial Barriers

Homogeneous trials present a missed opportunity to discover treatments that might be highly successful in a particular subset of patients.

Anna T. Levy, DO

Latest:

Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCC

Anna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.

Oladapo Yeku, MD, PhD, FACP

Latest:

Dr. Yeku on the Evaluation of COM701 Plus Nivolumab in Platinum-Resistant Ovarian Cancer

Oladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.